A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer

Summary

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 in combination with a checkpoint inhibitor compared to standard first-line therapy in participants with Extensive-Stage Small Cell Lung Cancer.

Conditions

• Extensive-Stage Small Cell Lung Cancer

Interventions

COMBINATION_PRODUCT

ZL-1310 in combination with Atezolizumab or Durvalumab

ZL-1310 ADC in combination with checkpoint inhibitor

COMBINATION_PRODUCT

Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin

Platinum-based chemotherapy in combination with a checkpoint inhibitor

COMBINATION_PRODUCT

Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance

Standard of Care Platinum-based chemotherapy in combination

Sponsors & Collaborators

• Zai Lab (US) LLC

  collaborator INDUSTRY

• Zai Lab (Shanghai) Co., Ltd.

  lead INDUSTRY

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-12-31

Primary Completion

2030-06-30

Completion

2031-06-30

FDA Drug

Yes